百济神州：聘任公司全球研发负责人汪来博士担任公司总裁、全球研发负责人

Group 1 - The core point of the article is the appointment of Dr. Wang Lai as the new president and global head of R&D for BeiGene, which was approved by the company's board of directors [1] - For the year 2024, BeiGene's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the report, BeiGene's market capitalization stands at 418.6 billion yuan [1]